Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $11.02, but opened at $10.40. Indivior shares last traded at $10.49, with a volume of 88,375 shares trading hands.
Analyst Upgrades and Downgrades
INDV has been the subject of a number of research reports. RODMAN&RENSHAW raised shares of Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price objective (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th. Finally, Rodman & Renshaw assumed coverage on shares of Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock.
View Our Latest Stock Analysis on INDV
Indivior Stock Down 0.4 %
The company's 50-day moving average is $11.77 and its 200-day moving average is $11.05. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -238.44 and a beta of 0.73.
Institutional Investors Weigh In On Indivior
Several hedge funds and other institutional investors have recently added to or reduced their stakes in INDV. VELA Investment Management LLC lifted its stake in shares of Indivior by 722.9% in the 3rd quarter. VELA Investment Management LLC now owns 123,435 shares of the company's stock valued at $1,212,000 after purchasing an additional 108,435 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Indivior in the fourth quarter valued at about $359,000. Stifel Financial Corp purchased a new position in Indivior during the third quarter worth about $100,000. AlphaCentric Advisors LLC purchased a new stake in shares of Indivior in the 3rd quarter valued at approximately $2,364,000. Finally, Clark Estates Inc. NY acquired a new position in shares of Indivior in the 3rd quarter worth approximately $2,477,000. Institutional investors and hedge funds own 60.33% of the company's stock.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
